NEOVACS

neovacs-logo

Neovacs, a spin-off from the Pierre & Marie Curie University in Paris, was founded on 1993 by Professor Daniel Zagury, one of France's most eminent immunologists and AIDS experts. Neovacs holds a broad patent portfolio and is developing several therapeutic vaccines for the treatment of AIDS, cancer and auto-immune & allergic diseases. Neovacs is acknowledged as a pioneer in the development of novel therapeutic vaccines against human cytokines (kinoids) and immunosuppressive viral proteins (toxoi... ds). At present, monoclonal antibodies are widely used to neutralize cytokines and treat patients suffering from cytokine-related diseases. In contrast to exogenous therapies with monoclonal antibodies, Neovacs' therapeutic vaccines induce a powerful, natural polyclonal antibody response in the patient.

#SimilarOrganizations #People #Financial #Website #More

NEOVACS

Social Links:

Industry:
Biotechnology Health Care Medical Device Therapeutics

Founded:
1993-01-01

Address:
Paris, Ile-de-France, France

Country:
France

Website Url:
http://www.neovacs.fr

Total Employee:
11+

Status:
Active

Contact:
33 1 53 10 93 00

Email Addresses:
[email protected]

Total Funding:
44.79 M USD

Technology used in webpage:
IPv6 Pound Sterling Japanese Yen 1and1


Similar Organizations

affimed-logo

Affimed

Affimed Therapeutics is focused on developing recombinant antibody therapeutics for the treatment of cancer and other diseases.

apellis-pharmaceuticals-logo

Apellis Pharmaceuticals

Apellis Pharmaceuticals focuses on developing novel therapeutics and drug delivery technologies to address chronic inflammatory diseases.

apogenix-logo

Apogenix

Apogenix is a biopharmaceutical company developing novel protein therapeutics for the treatment of cancer and inflammatory diseases.

cedilla-therapeutics-logo

Cedilla Therapeutics

Cedilla Therapeutics is a biotechnology company that develops targeted small molecules for the treatment of cancer and other diseases.

milestone-pharmaceuticals-logo

Milestone Pharmaceuticals

Milestone Pharmaceuticals is a drug development company developing small molecule therapeutics for the treatment of cardiovascular diseases.

not_available_image

Piramed

Piramed Limited, a biotech company, discovers and develops new medicines for the treatment of cancer and immune inflammatory disorders.

spero-therapeutics-logo

Spero Therapeutics

Spero Therapeutics develops therapeutics for treatment of gram-negative infections.


Current Advisors List

jean-jacques-bertrand_image

Jean-Jacques Bertrand Chairman @ Neovacs
Board_member

Current Employees Featured

miguel-sieler_image

Miguel Sieler
Miguel Sieler Chief Executive Officer @ Neovacs
Chief Executive Officer

vincent-serra_image

Vincent Serra
Vincent Serra Chief Scientific Officer @ Neovacs
Chief Scientific Officer

not_available_image

Daniel Zagury
Daniel Zagury Founder @ Neovacs
Founder

charlène-masson_image

Charlène Masson
Charlène Masson Corporate Communication Director @ Neovacs
Corporate Communication Director

Founder


not_available_image

Daniel Zagury

Stock Details


Company's stock symbol is EPA:ALNEV

Investors List

blue-ocean-advisors_image

Alpha Blue Oceanâ„¢

Alpha Blue Oceanâ„¢ investment in Post-IPO Debt - Neovacs

bpifrance_image

Bpifrance

Bpifrance investment in Post-IPO Equity - Neovacs

novartis-venture-fund_image

Novartis Venture Fund

Novartis Venture Fund investment in Venture Round - Neovacs

truffle-capital_image

Truffle Capital

Truffle Capital investment in Venture Round - Neovacs

debiopharm-innovation-fund_image

Debiopharm Innovation Fund

Debiopharm Innovation Fund investment in Venture Round - Neovacs

Investments List

Date Company Article Money raised
2021-10-20 Signia Therapeutics Neovacs investment in Series A - Signia Therapeutics 1.3 M EUR
2021-09-27 Bio-Detection K9 Neovacs investment in Venture Round - Bio-Detection K9 5 M USD

Official Site Inspections

http://www.neovacs.fr

  • Host name: 217-160-0-99.elastic-ssl.ui-r.com
  • IP address: 217.160.0.99
  • Location: Germany
  • Latitude: 51.2993
  • Longitude: 9.491
  • Timezone: Europe/Berlin

Loading ...

More informations about "Neovacs"

Accueil - Neovacs

May 15, 2020 Missions. Nous avons deux types d'activités distinctes : une activité de Recherche et Développement et une activité d'investissement. Nous développons nos produits propres autour de notre plateforme technologique …See details»

Home - Neovacs

May 15, 2020 Missions. Neovacs has two main activities: Research and Development activity, and investment activity. We are developing our own technology platform for Kinoid products used in lupus disease and allergies. …See details»

Historique de la société - Neovacs

Fondée en 1993 comme spin-off de Paris Sorbonne (ex Université Pierre et Marie Curie), nous avons pour ambition de développer nos produits Kinoïde, issus de technologies brevetées, et …See details»

Neovacs - Crunchbase Company Profile & Funding

Neovacs, a spin-off from the Pierre & Marie Curie University in Paris, was founded on 1993 by Professor Daniel Zagury, one of France's most eminent …See details»

NEOVACS - LinkedIn

NEOVACS | 1,317 followers on LinkedIn. Nous développons les thérapies de demain et investissons dans des sociétés innovantes en Biotech et Medtech | Neovacs, a French Biotechnology company ...See details»

NEOVACS - Societe.com

NEOVACS, société anonyme à conseil d'administration, immatriculée sous le SIREN 391014537, est en activité depuis 31 ans. Située à SURESNES (92150), elle est spécialisée dans le …See details»

Neovacs Company Profile - Office Locations, Competitors ... - Craft

Sep 26, 2024 Neovacs is a French biotechnology company developing the next generation of therapeutic vaccines for autoimmune and inflammatory diseases and certain types of cancers. …See details»

Neovacs S.A. (EPA: ALNEV) Company Profile & Overview - Stock …

Jan 16, 2025 Neovacs S.A., a biotechnology company, focuses on the development of therapeutic vaccines for the treatment of autoimmune, inflammatory, allergy, and cancer …See details»

Startup NEOVACS Leader de la vaccination thérapeutique

Leader de la vaccination thérapeutique. Néovacs est une société de biotechnologie française spécialisée dans la recherche et le développement de vaccins thérapeutiques pour le …See details»

NEOVACS (EPA:ALNEV) | Néovacs co-organise la 1ère rencontre …

21 hours ago [email protected] 01 53 67 36 78: Anne-Charlotte DUDICOURT Relations Presse financière [email protected] 06 24 03 26 52: Avertissement : La société Néovacs a mis en …See details»

NEOVACS - Sur la base d'une valorisation indépendante de son …

Suresnes, le 6 mars 2025 – 8h CET - Néovacs (Euronext Growth Paris : ALNEV), société biopharmaceutique à un stade préclinique développant de nouvelles thérapies pour des …See details»

Footer Small Print Menu - Euronext Live

Mar 6, 2025 Pour plus d'informations : www.neovacs.fr. Jérôme FABREGUETTES-LEIB Relations Investisseurs [email protected] 01 53 67 36 78 Anne-Charlotte DUDICOURT …See details»

NEOVACS : Néovacs co-organise la 1ère rencontre ... - Boursorama

21 hours ago Jérôme FABREGUETTES-LEIB Relations Investisseurs [email protected] 01 53 67 36 78 Anne-Charlotte DUDICOURT Relations Presse financière [email protected] 06 …See details»

Neovacs - Information réglementée

Jan 8, 2025 Recevez gratuitement par e-mail toute l'information financière de NEOVACS en vous inscrivant ici. Choisissez une année... 2025 2025 2024 2023 2022 2021 2020 2019 2018 …See details»

NEOVACS Cours Action ALNEV, Cotation Bourse Euronext Paris

Le cours de l'action NEOVACS ALNEV en temps réel sur Boursorama : historique de la cotation sur Euronext Paris, graphique, actualités, consensus des analystes et informations boursièresSee details»

Néovacs étudie une sortie de la Bourse pour valoriser au mieux ses ...

Feb 4, 2025 Pour plus d'informations : www.neovacs.fr. Jérôme FABREGUETTES-LEIB Relations Investisseurs [email protected] 01 53 67 36 78 Anne-Charlotte DUDICOURT …See details»

Néovacs a présenté les derniers résultats de son candidat-vaccin à …

Mar 4, 2025 [email protected] 01 53 67 36 78: Anne-Charlotte DUDICOURT Relations Presse financière [email protected] 06 24 03 26 52: Avertissement : La société Néovacs a mis en …See details»

NEOVACS : L'Agence nationale de la recherche (ANR) soutient le ...

Jan 10, 2025 Jérôme FABREGUETTES-LEIB Relations Investisseurs [email protected] 01 53 67 36 78 Anne-Charlotte DUDICOURT Relations Presse financière [email protected] 06 …See details»

Footer Small Print Menu - Euronext Live

Mar 4, 2025 Deux des plus grands rassemblements américains et européen sur les nouvelles approches innovantes en ARNm ont retenu les projets de Neovacs pour des présentations …See details»

Neovacs : Ajustement de la valeur nominale - Zonebourse.com

Jan 15, 2025 [email protected] 01 53 67 36 78 Anne-Charlotte DUDICOURT Relations Presse financière [email protected] 06 24 03 26 52: Avertissement : La société Néovacs a mis en …See details»

linkstock.net © 2022. All rights reserved